Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MGTI 4.18 0.23 +5.82 1,079,486 4.17 4.18
Close watch, $VII 0.526 0.1159 +28.26 224,076 0.52 0.5434
$MGTI 3.958 0.518 +15.06 2,563,081 3.94 3.96
Alerted around 1.70
Good Morning all!
UNXL 0.127 0.0642 +102.23 81,819,572 0.124 0.127
Good call, $UNXL 0.096 0.0332 +52.87 18,156,191 0.0959 0.096
Nice, $MGTI 3.13 0.23 +7.93 690,268 3.13 3.14
Good Morning Dip & Rippers!
$TNDM 1.1801 0.4799 +68.54 9,548,485 1.18 1.19
$TNDM 0.7002 0.00 0.00 188,394 0.92 0.939
Tandem Diabetes Care Announces FDA Approval and Launch of t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration
41 minutes ago - DJNF
-- Software Update Available for Current t:slim X2 Pump Users Via Personal Computer --
SAN DIEGO--(BUSINESS WIRE)--August 28, 2017--
Tandem Diabetes Care(R), Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval and commercial launch of the t:slim X2(TM) Insulin Pump with Dexcom G5(R) Mobile continuous glucose monitoring (CGM) integration, the first sensor-augmented insulin pump approved to let users make treatment decisions without pricking their finger(1) . The software featured on this pump will also be available to current t:slim X2 Pump users at no cost via remote software update, allowing them to add CGM integration to their existing pumps from home using a personal computer. Individual emails are being sent directly to t:slim X2 Pump customers with instructions on how to perform the update. The t:slim X2 Pump with Dexcom G5 Mobile CGM integration is approved for ages 6 and older.
This approval marks the Company's fifth new insulin pump launch in only 5 years and the second featuring Dexcom technology. It is the only available pump that conveniently displays a user's insulin delivery activity and Dexcom G5 Mobile CGM data together on a single device. The t:slim X2 Pump is also the only insulin pump capable of remote software updates(2) , allowing existing users to add features like CGM integration from home. It is up to 38% smaller than other pumps(3) , but includes advanced features like a large color touchscreen, Bluetooth(R) radio, rechargeable battery, USB connectivity, 300-unit insulin capacity and watertight construction (IPX7)(4) .
"We are setting a new standard in our industry by simultaneously offering our existing and future customers the benefits of best-in-class CGM integration on our simple-to-use touchscreen insulin pump," said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. "The t:slim X2 Pump is designed to accelerate the pace in which we can bring new innovations to people with diabetes, which is of particular importance as we develop software updates to add automated insulin delivery algorithms to our platform."
"Dexcom has been moving its technology forward at a rapid pace, and Tandem's ability to roll out remote software updates like this opens up exciting possibilities for faster integrations of our future products," said Steve Pacelli, Executive Vice President of Strategy and Corporate Development at Dexcom. "We are excited to have our latest CGM technology integrated with their t:slim X2 Insulin Pump, and to see it offered not only to new customers but also to existing t:slim X2 Pump users."
The t:slim X2 Pump can operate as a stand-alone insulin pump without CGM, or be paired with the Dexcom G5 Mobile CGM to track glucose continuously and display that information directly on the pump's home screen. Dexcom G5 Mobile is the only CGM system FDA approved to let users make treatment decisions without pricking their finger. Dexcom is also consistently rated the #1 CGM brand in independent patient surveys(5) . In addition to integration with the t:slim X2 Pump, dynamic glucose data from the Dexcom G5 Mobile CGM can be easily accessed and shared using a compatible mobile device.
For additional t:slim X2 Pump product and safety information, or to begin the order process, visit
www.tandemdiabetes.com/tslimX2
or call 877-801-6901, Monday -- Friday between 6am and 5pm Pacific Time
Download Tandem's free t:simulator(TM) App to experience the touchscreen interface of the t:slim X2 Pump with Dexcom G5 Mobile CGM integration directly on your mobile device. For more information and to download the app, visit http://www.tandemdiabetes.com/tsimulator.
Information for Current t:slim X2 Pump Users
All eligible t:slim X2 Pump users have the option to add Dexcom G5 Mobile CGM integration via a software update using a personal computer. Individual emails are being sent directly to t:slim X2 Pump customers with instructions on how to perform the update. The software update is Mac(R) and PC compatible. For more information on system requirements, visit www.tandemdiabetes.com/updater.
Remote Software Updates for Insulin Pumps
Tandem is the only company with a tool for providing remote software updates for its insulin pumps using a personal computer. The power of the t:slim X2 Pump's touchscreen allows for buttons to be moved and data like the interactive CGM screen to be added via software updates without getting a new device. With innovations in diabetes technology consistently moving faster than the typical insurance pump replacement cycle, remote software updates make it easier to make a purchasing decision today without worrying that the device will soon be outdated. Future Tandem products are being developed with software updates in mind, with the goal of delivering new technologies to both new and current customers at the same time.(2)
The Benefits of Insulin Pump Therapy with CGM
Published studies have shown that insulin pump therapy, when paired with proper training and support, can result in better blood sugar control and lower total daily insulin use compared to multiple daily injections.(6,7,8) CGM has demonstrated improved blood sugar control, increased confidence related to the risk of low blood sugar, and decreased diabetes stress.(9,10) Combining insulin pump therapy and CGM has demonstrated the best overall glucose control compared to multiple daily injections or pump therapy alone, in addition to the quality of life improvements associated with each individual therapy.(9)
Insulin Pump Use and Diabetes
Diabetes is a chronic, life-threatening disease that affects more than 29 million people in the United States, or nearly 1 in 10 Americans. Tandem estimates that more than 3 million people in the United States require daily administration of insulin and are candidates for pump therapy. More than 425,000 Americans with type 1 diabetes use an insulin pump, or approximately 27% of the type 1 diabetes population. In addition, approximately 125,000 Americans with type 2 diabetes use an insulin pump, a small fraction of the type 2 diabetes population.
The t:slim X2 Pump with Dexcom G5 Mobile CGM integration will replace the Company's previous-generation t:slim G4(TM) Pump. The Company will continue to service all current t:slim G4 Pumps for the duration of their warranty. An upgrade program is available through September 30, 2017, for t:slim and t:slim G4 Pump users interested in accessing the t:slim X2 Pump. For more information, visit www.tandemdiabetes.com/upgrade.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2(TM) Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex(R) Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care is a registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom, Inc. Bluetooth(R) is a registered trademark of Bluetooth SIG, Inc. All other trademarks are the property of their respective owners.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the Company's ability to develop software updates that add automated insulin delivery algorithms to the t:slim X2 and the potential for faster integration with Dexcom products in the future. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including the Company's ability to complete the development of automated insulin delivery algorithms for the t:slim X2, the Company's ability to successfully complete clinical trials for new products when anticipated (or at all), the potential that the results of any such clinical trials may not be sufficient to support regulatory approvals for new products as anticipated and the Company's ability to obtain regulatory approvals for future products and product features generally. Other risks and uncertainties are identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.
(1) CGM-based treatment requires fingersticks for calibration; may
result in hypoglycemia if calibration not performed, when taking
acetaminophen, or if symptoms/expectations do not match CGM
readings.
(2) Additional feature updates are not currently available for the
(MORE TO FOLLOW) Dow Jones Newswires
August 28, 2017 08:30 ET (12:30 GMT)
Tandem Diabetes Care Announces FDA Approval and -2-
t:slim X2 Pump with Dexcom G5 Mobile CGM integration and are subject
to future FDA approvals. Charges may apply.
(3) 38% smaller than MiniMed 630G and 670G and at least 28% smaller than
MiniMed 530G, Animas Vibe and Omnipod System. Data on file, Tandem
Diabetes Care.
(4) Tested to 3 feet for 30 minutes (IPX7 rating).
(5) dQ&A USA Diabetes Connections Surveys, 2009-2016.
(6) Reznik Y, Cohen O, Aronson R, et al. Lancet.
2014;384(9950):1265-1272.
(7) Hoogma RPLM, Hammond PJ, Gomis R, et al. Diabet Med.
2005;23:141-147.
(8) Bode BW, Sabbah HT, Gross TM. Diabet Metab Res Rev. 2002;18(suppl
1):S14-S20.
(9) Foster N, Miller K, Tamborlane W, Bergenstal R, Beck R, & T1D
Exchange Clinical Network (2016). Diabetes Care 2016 Jun; 39(6):
e81-e82.
(10) Polonsky B, Hessler D, Ruedy K, Beck R. & DIAMOND Study Group.
Diabetes Care. 2017. doi:10.2337/dc17-0133. [Epub ahead of print]
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005281/en/
CONTACT: For Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com
SOURCE: Tandem Diabetes Care®, Inc.
Copyright Business Wire 2017
(END) Dow Jones Newswires
August 28, 2017 08:30 ET (12:30 GMT)
News, $ANTH 1.29 0.00 0.00 24,026 1.36 1.40
Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
38 minutes ago - DJNF
Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
-- Trend toward preservation of renal function (eGFR) in blisibimod treated
patients
-- Lack of disease progression, as measured by proteinuria in blisibimod
treated patients
HAYWARD, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced top line final data from the extension of the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in 58 patients with IgA nephropathy (IgAN). Patients were treated for up to 2 years, and all patients had the opportunity to complete at least 60 weeks of treatment.
Throughout the treatment period and for up to one year of additional follow up off treatment, blisibimod appeared to halt disease progression as measured by the mean estimate of 24-hour urinary protein excretion levels, also known as proteinuria. Specifically, in patients treated with blisibimod, the mean change in proteinuria was stable to trending slightly downward, whereas the mean levels increased for patients in the placebo arm.
Estimated 24 Hour Urine Protein Excretion
Study Week 0 24 48 60 96 120 144 168
Blisibimod - mean (grams) 2.02 2.17 1.86 1.86 1.88 2.12 2.19 1.18
Placebo - mean (grams) 2.26 2.16 2.01 2.42 2.89 3.35 3.22 4.68
N (blisibimod) 30 27 27 26 20 12 5 3
N (placebo) 28 23 17 17 11 9 4 2
Additionally, blisibimod demonstrated a trend toward preservation of renal function based upon individual rates of change in estimated glomerular filtration rate (eGFR), with an annualized improvement of +6.2mL/min/1.73 m(2) per year compared to a worsening of -4.8 mL/min/1.73 m(2) of body surface area with placebo.
As seen with previous interim analyses of the BRIGHT data, serum immunoglobulins IgA, IgG, and IgM, continue to demonstrate marked reduction throughout the treatment period.
Blisibimod was well tolerated with substantially more patients on the placebo arm discontinuing from the study than those receiving blisibimod. The most common adverse events seen in the blisibimod group over the entire study period were upper respiratory infection, nasopharyngitis, and injection site reactions. There were no incidences of serious infection in the blisibimod group and the overall rates of infection were similar in the two treatment groups.
"We are very pleased with the final extension data and believe that the recent findings, as well as the orphan designation granted by the US Food and Drug Administration (US FDA) provide a strong rationale to continue the clinical development of blisibimod for the treatment of IgA nephropathy," shared Craig Thompson, President and CEO of Anthera. "We look forward to sharing these findings with the FDA and proceeding with a Phase 3 trial for patients with IgAN."
"It is good to see that the interim observations, that blisibimod may slow the worsening of proteinuria, persisted through the end of the study. The new observations showing long-term trends in preservation of glomerular filtration are exciting as these are goals for all IgAN therapies," said Professor Jonathan Barratt, PhD, FRCP, Reader, Department of Infection, Immunity & Inflammation, University of Leicester, U.K. "Finally, it is reassuring that blisibimod was well-tolerated; this contrasts with recent evidence of steroid risk in other trials."
About BRIGHT-SC
Fifty-eight (58) patients aged 18-65 with historical kidney biopsy proven IgAN (Oxford classification), persistent proteinuria (1-6 g/24hrs) despite treatment with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARB), and estimated glomerular filtration rate > 30mL/min/1.73m(2) were equally randomized to receive either blisibimod (300mg/wk for 8 weeks and 200mg/wk thereafter; n=30) or matching placebo (n=28) for at least 24 weeks. Patients with advanced glomerular or tubulointerstitial scarring or rapidly progressive glomerulonephritis were excluded. After Week 24, patients were given the opportunity to receive blinded treatment for up to 104 weeks, discontinue treatment but continue to be followed, or discontinue from the study. Fifty-seven (57) patients received at least one dose of study medication and were included in the efficacy (mITT) and safety evaluations. The study was ended when all ongoing patients had completed at least Week 60. Forty seven patients (27 blisibimod, 20 placebo) completed at least 24 weeks of evaluation, 43 completed at least 60 weeks of evaluation, and 22 completed assessments through at least 108 weeks.
The study population was balanced between treatment groups with respect to age, weight, BMI, demographic and disease characteristics. Patients were enrolled from Asia (74%) and Europe (26%). All patients were taking an ARB and 52% were also taking an ACEi. Mean time since diagnosis was 2.2 years, mean estimated 24-hour urine protein was 2.14 grams, mean estimated glomerular filtration rate 68.25 ml/min/1.73 m(2) body surface area, and mean kidney biopsy Oxford Classification Derived Score was 6.2.
All patients were treated with an optimal, stable dose of ACEi and/or ARB for a minimum of 90 days prior to randomization and this therapy was continued throughout the trial as background medication. Patients were not allowed to receive corticosteroids for the treatment of IgA nephropathy within 3 months or immunosuppressives within 6 months of screening; however, these medications could be initiated as rescue treatment after randomization.
The BRIGHT-SC study was originally designed as a two-part Phase 2/3 study with a target enrollment of 200 patients. Part A was a 24-Week study of the effects of blisibimod on proteinuria, and Part B was an extension phase in which long term effects on the prevention of end stage renal disease would be assessed. The primary endpoint of the study was the number of patients who achieved a partial or complete response in urinary protein excretion at Week 24. A partial response was defined as achieving proteinuria <=1g 4hrs,="" and="" a="" complete="" response="" as="" follows:="" for="" patients="" with="" baseline="" proteinuria="">=1g/24hrs but <=2g 4hrs,="" achievement="" of="" proteinuria=""><=1.0g 4hr="" and="" a="" 50%="" reduction="" from="" baseline="" at="" 2="" consecutive="" visits;="" for="" patients="" with="" baseline="" proteinuria=""> 2g/24hrs, achievement of proteinuria <=1.0g 4hr="" or="" a="" 50%="" reduction="" from="" baseline="" at="" 2="" consecutive="" visits.="" due="" to="" slow="" recruitment,="" enrollment="" was="" curtailed="" at="" 58="" patients="" and="" the="" study="" was="" converted="" to="" a="" phase="" 2="" study.="" an="" observed="" case,="" interim="" analysis="" was="" conducted="" when="" all="" patients="" had="" the="" opportunity="" to="" complete="" week="" 24="" and="" another="" at="" week="" 48,="" results="" of="" which="" were="" previously="" announced.="" mean="" effects="" by="" treatment="" group="" on="" proteinuria="" and="" certain="" measures="" of="" expected="" pharmacology="" (circulating="" b="" cells="" and="" b="" cell="" subpopulations,="" serum="" immunoglobulins)="" were="" analyzed="" and="" reported="" to="" anthera="" by="" an="" independent="" statistician,="" with="" the="" treatment="" blind="" maintained="" for="" the="" patient,="" investigator,="" and="" sponsor="" personnel.="">
About IgA Nephropathy
IgA nephropathy (IgAN, also known as Berger's disease) is the most common cause of primary glomerulonephritis worldwide, occurring more frequently in Asia than in Europe or North America. Patients express under-glycosylated immunoglobulin A1 (IgA1) which is immunogenic and targeted by other immunoglobulins. The resulting IgA-containing immune complexes are deposited in the kidney, causing inflammation with consequent blood and protein leakage into the urine. The disease typically progresses slowly, but as many as 40-50% of adults will eventually develop end-stage-renal disease and require dialysis or kidney transplant. The current management of IgAN is non-specific treatment aimed at blood pressure control and reduction of proteinuria with angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II receptor blockers (ARBs); corticosteroids and immunosuppressive therapy are used in some patients but benefits are uncertain.
About Blisibimod
Blisibimod is a selective peptibody antagonist of the B-cell activating factor (BAFF) cytokine. BAFF is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. It is primarily expressed by macrophages, monocytes and dendritic cells and interacts with three different receptors on B-cells: BAFF receptor, or BAFF-R; B-cell maturation antigen, or BCMA; and transmembrane activator and cyclophilin ligand interactor, or TACI. BAFF-R is expressed primarily on peripheral B-cells. Blisibimod consists of a novel BAFF binding domain fused to the N-terminus of the Fc region of human IgG1 antibody. Blisibimod binds to both membrane and soluble BAFF, and inhibits the interaction of BAFF with its receptors.
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on Anthera can be found at www.anthera.com.
Safe Harbor Statement
(MORE TO FOLLOW) Dow Jones Newswires
August 28, 2017 08:30 ET (12:30 GMT)
Anthera Announces Top Line Final Data from the -2-
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Contact Information
CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc.
ir@anthera.com
For Media Inquiries:
Frannie Marmorstein
rbb Communications
frannie.marmorstein@rbbcommunications.com
305-567-0821
www.twitter.com/antherapharma
https://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals
(END) Dow Jones Newswires
August 28, 2017 08:30 ET (12:30 GMT)
On news, $EYES 1.00 0.00 0.00 41,050 1.07 1.14
Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study
25 minutes ago - DJNF
SYLMAR, Calif.--(BUSINESS WIRE)--August 28, 2017--
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin the Orion(TM) Cortical Visual Prosthesis System (Orion) feasibility clinical study. The conditional approval allows two U.S. sites to enroll up to five total patients. The FDA has also requested that the Company conduct additional device testing and address outstanding questions. Second Sight has 45 days to respond to FDA's requests.
"This is an exciting milestone for the Company given the potential of Orion to provide useful vision to millions of blind individuals worldwide who have no other option today. We are delighted to have received conditional approval from the FDA to move forward and can now focus on finalizing the various approvals and agreements required at each clinical trial site. Once we complete those steps, our designated U.S. clinical trial sites, the University of California at Los Angeles (UCLA) and Baylor College of Medicine (Baylor) in Houston, can begin patient recruitment efforts. The Orion team has met all major internal milestones this year and we remain on-track to achieve the Company's stated goal of implanting our first Orion patient before year end," stated Will McGuire, President and Chief Executive Officer of Second Sight.
"The ability to implant the first Orion system, which has the potential to treat nearly all forms of profound blindness, has been a stated goal of the Company since our IPO. We are grateful for the rapid review and approval by the FDA. This milestone is a testament to the careful, high-quality work completed by the Second Sight and UCLA teams to date. We look forward to continuing our work with UCLA as this exciting clinical trial begins and also welcome Baylor to this important effort," stated Dr. Robert Greenberg, Chairman of the Board.
Blind patients interested in the Orion clinical trial can contact Second Sight customer service at 1-855-756-3703.
About the Orion Visual Cortical Prosthesis System
Second Sight, the manufacturer of the Argus II Retinal Prosthesis System (Argus II), has developed a new device, the Orion. A proof-of-concept clinical trial demonstrating the viability of stimulation of the human visual cortex with a commercially available device from a different manufacturer began in Q4 2016 at UCLA. First-in-human clinical studies with the Orion are planned in 2017. Like the Argus II, the idea behind Second Sight's Orion is to convert images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses. The Orion is designed to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the visual cortex, intended to result in the perception of patterns of light. By bypassing the retina and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to restore useful vision to patients completely blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses stimulate the retina's remaining cells, intending to result in the perception of patterns of light in the brain. The patient must learn to interpret these visual patterns, having the potential to regain some visual function. The Argus II was the first artificial retina to receive widespread commercial approval, and is offered at approved centers in Canada, France, Germany, Italy, Russia, Saudi Arabia, South Korea, Spain, Taiwan, Turkey, United Kingdom, and the U.S.
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and now manufactures and markets the Argus(R) II Retinal Prosthesis System. Enrollment has been completed in a feasibility trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion(TM) Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should" and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 16, 2017, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005313/en/
CONTACT: Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Managing Director
greg.falesnik@mzgroup.us
SOURCE: Second Sight Medical Products, Inc.
Copyright Business Wire 2017
(END) Dow Jones Newswires
August 28, 2017 08:00 ET (12:00 GMT)
Holy crap!
Holy crap!
$UNXL 0.27 0.022 +8.88 1,507,812 0.27 0.2729
$ABIL 1.135 0.2951 +35.14 2,611,442 1.13 1.14
See you all later!
? $UNXL 0.248 0.00 0.00 15,950 0.25 0.259
Nice, $ABIL 0.8399 0.00 0.00 129 0.94 0.98
Good morning all!
MGTI 2.81 0.31 +12.40 1,647,539 2.80 2.81
$ABIL 0.8598 0.1598 +22.83 513,822 0.8551 0.8596
$ABIL 0.8351 0.1351 +19.30 496,142 0.8351 0.844
Close watch, $ABIL 0.70 0.00 0.00 1,532 0.7136 0.74
$MGTI 2.50
Thanks, Hope we can help each other make some money.
Just got back from vacation!
Thanks, I'm back. Had a great time.
Bought a summer get a way.
Life is good!
Hey buddy, How you been?
Just got back from a well deserved vacation.
Went up to new england, Spent time with great friends.
Thanks for joining us on the new board.
Now let us all make some bucks $$$
$SGYP $TEUM $TROV close watch!
Morning movers, $HMNY $HMY $IDXG $OCN
Also watch $MUX
CHARTS: Mining once again one of biggest drivers of US economy
http://www.mining.com/mining-once-again-one-of-biggest-drivers-of-us-economy/?utm_source=digest-en-mining-170815&utm_medium=email&utm_campaign=digest
$IDXG After Hours: 1.20 +0.12 (11.11%)
Thank you, You too. Have and best of luck!
$IDXG 1.03 0.2025 +24.47 5,440,969 1.03 1.04
Price Open 0.89
Previous Close 0.8275
Day High 1.05
Day Low 0.8825
25 Stocks Moving In Tuesday's Pre-Market Session
https://www.benzinga.com/news/17/08/9932403/25-stocks-moving-in-tuesdays-pre-market-session
UK lithium start-up gets $1.3 million to build new mine in Cornwall
http://www.mining.com/uk-lithium-start-gets-1-3-million-build-new-mine-cornwall/?utm_source=digest-en-mining-170814&utm_medium=email&utm_campaign=digest
Thanks, I hope the striped Bass are biting!
Something is up, $IDXG 0.8275 0.00 0.00 41,385 0.96 0.97
Good Morning, Tomorrow vacation time.
New england bound!
Thanks for the updates!
Hey buddy, Thank you. https://investorshub.advfn.com/Nasdaq-Dip-&-Rip-32462/